Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects

The inefficiency of recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based clinical regimens has been dominantly attributed to the short half-life of TRAIL. Affinity-controlled release using endogenous long-acting proteins, such as IgG and albumin, as carriers is extremely...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hao, Feng, Yanru, Cai, Huawei, Jia, Dianlong, Li, Heng, Tao, Ze, Zhong, Yi, Li, Zhao, Shi, Qiuxiao, Wan, Lin, Li, Lin, Lu, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928902/
https://www.ncbi.nlm.nih.gov/pubmed/29721092
http://dx.doi.org/10.7150/thno.23880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928902/
https://www.ncbi.nlm.nih.gov/pubmed/29721092
http://dx.doi.org/10.7150/thno.23880

Ejemplares similares